LEVO-T Drug Patent Profile
When do Levo-t patents expire, and what generic alternatives are available?
Levo-t is a drug marketed by Cediprof Inc and is included in one NDA.
The generic ingredient in LEVO-T is levothyroxine sodium. There is one drug master file entry for this compound. Fifty suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Levo-t
A generic version of LEVO-T was approved as levothyroxine sodium by MYLAN on June 5th, 2002.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for LEVO-T?
- What are the global sales for LEVO-T?
- What is Average Wholesale Price for LEVO-T?
Summary for LEVO-T
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 7 |
| Raw Ingredient (Bulk) Api Vendors: | 73 |
| Patent Applications: | 2,604 |
| Drug Prices: | Drug price information for LEVO-T |
| What excipients (inactive ingredients) are in LEVO-T? | LEVO-T excipients list |
| DailyMed Link: | LEVO-T at DailyMed |
US Patents and Regulatory Information for LEVO-T
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cediprof Inc | LEVO-T | levothyroxine sodium | TABLET;ORAL | 021342-001 | Mar 1, 2002 | AB1,AB2,AB3 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Cediprof Inc | LEVO-T | levothyroxine sodium | TABLET;ORAL | 021342-007 | Mar 1, 2002 | AB1,AB2,AB3 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Cediprof Inc | LEVO-T | levothyroxine sodium | TABLET;ORAL | 021342-004 | Mar 1, 2002 | AB1,AB2,AB3 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Cediprof Inc | LEVO-T | levothyroxine sodium | TABLET;ORAL | 021342-011 | Mar 1, 2002 | AB1,AB2,AB3 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Cediprof Inc | LEVO-T | levothyroxine sodium | TABLET;ORAL | 021342-012 | Dec 8, 2003 | AB1,AB2,AB3 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Cediprof Inc | LEVO-T | levothyroxine sodium | TABLET;ORAL | 021342-002 | Mar 1, 2002 | AB1,AB2,AB3 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LEVO-T
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cediprof Inc | LEVO-T | levothyroxine sodium | TABLET;ORAL | 021342-010 | Mar 1, 2002 | 6,399,101 | ⤷ Start Trial |
| Cediprof Inc | LEVO-T | levothyroxine sodium | TABLET;ORAL | 021342-004 | Mar 1, 2002 | 6,399,101 | ⤷ Start Trial |
| Cediprof Inc | LEVO-T | levothyroxine sodium | TABLET;ORAL | 021342-008 | Mar 1, 2002 | 6,399,101 | ⤷ Start Trial |
| Cediprof Inc | LEVO-T | levothyroxine sodium | TABLET;ORAL | 021342-011 | Mar 1, 2002 | 6,399,101 | ⤷ Start Trial |
| Cediprof Inc | LEVO-T | levothyroxine sodium | TABLET;ORAL | 021342-001 | Mar 1, 2002 | 6,399,101 | ⤷ Start Trial |
| Cediprof Inc | LEVO-T | levothyroxine sodium | TABLET;ORAL | 021342-009 | Mar 1, 2002 | 6,399,101 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LEVO-T
See the table below for patents covering LEVO-T around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2001252953 | ⤷ Start Trial | |
| Australia | 5295301 | ⤷ Start Trial | |
| Brazil | 0109736 | ⤷ Start Trial | |
| Canada | 2404369 | ⤷ Start Trial | |
| European Patent Office | 1267999 | ⤷ Start Trial | |
| Israel | 152024 | PHARMACEUTICAL COMPOSITIONS CONTAINING THYROID HORMONE AND PROCESSES FOR THE MANUFACTURE THEREOF | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch